NL9101680A - Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren. - Google Patents

Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren. Download PDF

Info

Publication number
NL9101680A
NL9101680A NL9101680A NL9101680A NL9101680A NL 9101680 A NL9101680 A NL 9101680A NL 9101680 A NL9101680 A NL 9101680A NL 9101680 A NL9101680 A NL 9101680A NL 9101680 A NL9101680 A NL 9101680A
Authority
NL
Netherlands
Prior art keywords
cells
bone marrow
mulv
recombinant
gene
Prior art date
Application number
NL9101680A
Other languages
English (en)
Dutch (nl)
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tno filed Critical Tno
Priority to NL9101680A priority Critical patent/NL9101680A/nl
Priority to EP92921536A priority patent/EP0606376B1/de
Priority to DE69225489T priority patent/DE69225489T2/de
Priority to PCT/NL1992/000177 priority patent/WO1993007281A1/en
Priority to JP5506806A priority patent/JPH07501690A/ja
Priority to CA002120370A priority patent/CA2120370A1/en
Priority to AU27689/92A priority patent/AU2768992A/en
Priority to ES92921536T priority patent/ES2118140T3/es
Priority to AT92921536T priority patent/ATE166109T1/de
Priority to US08/211,342 priority patent/US5612206A/en
Publication of NL9101680A publication Critical patent/NL9101680A/nl
Priority to US08/820,479 priority patent/US6472212B1/en
Priority to US10/164,076 priority patent/US20030166285A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL9101680A 1991-10-04 1991-10-04 Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren. NL9101680A (nl)

Priority Applications (12)

Application Number Priority Date Filing Date Title
NL9101680A NL9101680A (nl) 1991-10-04 1991-10-04 Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
CA002120370A CA2120370A1 (en) 1991-10-04 1992-10-05 Method for genetically modifying bone marrow cells of primates, and useful cells therefor that produce recombinant retroviral vectors
DE69225489T DE69225489T2 (de) 1991-10-04 1992-10-05 Methode zur genetischen veränderung von knochenmarkzellen von primaten und dafür brauchbare zellen, die rekombinante retrovirale vektoren produzieren
PCT/NL1992/000177 WO1993007281A1 (en) 1991-10-04 1992-10-05 Method for genetically modifying bone marrow cells of primates, and useful cells therefor that produce recombinant retroviral vectors
JP5506806A JPH07501690A (ja) 1991-10-04 1992-10-05 霊長類の骨髄細胞を遺伝的に修飾する方法、および該方法のために有用な、組換えレトロウイルスベクターを産生する細胞
EP92921536A EP0606376B1 (de) 1991-10-04 1992-10-05 Methode zur genetischen veränderung von knochenmarkzellen von primaten und dafür brauchbare zellen, die rekombinante retrovirale vektoren produzieren
AU27689/92A AU2768992A (en) 1991-10-04 1992-10-05 Method for genetically modifying bone marrow cells of primates, and useful cells therefor that produce recombinant retroviral vectors
ES92921536T ES2118140T3 (es) 1991-10-04 1992-10-05 Procedimiento de modificacion genetica de las celulas de la medula osea de primates, y celulas utilizables y celulas que producen vectores retrovirales recombinados.
AT92921536T ATE166109T1 (de) 1991-10-04 1992-10-05 Methode zur genetischen veränderung von knochenmarkzellen von primaten und dafür brauchbare zellen, die rekombinante retrovirale vektoren produzieren
US08/211,342 US5612206A (en) 1991-10-04 1992-10-05 Retrovirus infecting primate bone marrow cells and harvesting both non-adherent and adherent cells
US08/820,479 US6472212B1 (en) 1991-10-04 1997-03-18 Methods and compositions for genetically modifying primate bone marrow cells
US10/164,076 US20030166285A1 (en) 1991-10-04 2002-06-04 Methods and compositions for genetically modifying primate bone marrow cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL9101680A NL9101680A (nl) 1991-10-04 1991-10-04 Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
NL9101680 1991-10-04

Publications (1)

Publication Number Publication Date
NL9101680A true NL9101680A (nl) 1993-05-03

Family

ID=19859782

Family Applications (1)

Application Number Title Priority Date Filing Date
NL9101680A NL9101680A (nl) 1991-10-04 1991-10-04 Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.

Country Status (10)

Country Link
US (3) US5612206A (de)
EP (1) EP0606376B1 (de)
JP (1) JPH07501690A (de)
AT (1) ATE166109T1 (de)
AU (1) AU2768992A (de)
CA (1) CA2120370A1 (de)
DE (1) DE69225489T2 (de)
ES (1) ES2118140T3 (de)
NL (1) NL9101680A (de)
WO (1) WO1993007281A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
NL9101680A (nl) * 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
US6051427A (en) * 1993-06-11 2000-04-18 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
CA2168202A1 (en) * 1993-07-30 1995-03-16 Joseph Dougherty Efficient gene transfer into primary lymphocytes
WO1996035798A1 (en) * 1995-05-10 1996-11-14 Introgene B.V. Improved retroviral vectors, especially suitable for gene therapy
NZ337945A (en) * 1997-03-18 2001-10-26 Introgene B Combining primate bone marrow cells with a recombinant retrovirus using a physical means to bring them into close physical contact
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
US6300127B1 (en) 1997-07-30 2001-10-09 Emory University Bone mineralization proteins, DNA, vectors, expression systems
CN1190496C (zh) * 1998-07-01 2005-02-23 宝生物工程株式会社 基因导入的方法
CN1342206A (zh) * 1998-08-28 2002-03-27 杜克大学 在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒
ES2241599T3 (es) * 1999-05-10 2005-11-01 Chugai Seiyaku Kabushiki Kaisha Metodo de cultivo de celulas.
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6534300B1 (en) * 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6905856B2 (en) 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
ES2198216B1 (es) * 2002-07-02 2005-04-16 Juan Carlos Instituto Cientifico Y Tecnologico De Navarra, S.A.(67%). Medio de cultivo de celulas madre-progenitoras autologas humanas y sus aplicaciones.
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
EP3652296A1 (de) * 2017-09-20 2020-05-20 The Charles Stark Draper Laboratory Inc. Vorrichtung zur effizienten genetischen modifikation von zellen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198423A (en) 1989-05-26 1993-03-30 Takara Shuzo Co., Ltd. Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
NL9101680A (nl) * 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5534423A (en) * 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
US5686278A (en) 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
US5811274A (en) 1994-12-09 1998-09-22 The Regents Of The University Of Michigan Methods, compositions and apparatus for cell transfection
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie

Also Published As

Publication number Publication date
AU2768992A (en) 1993-05-03
EP0606376A1 (de) 1994-07-20
ATE166109T1 (de) 1998-05-15
CA2120370A1 (en) 1993-04-15
US20030166285A1 (en) 2003-09-04
DE69225489T2 (de) 1999-01-07
ES2118140T3 (es) 1998-09-16
JPH07501690A (ja) 1995-02-23
EP0606376B1 (de) 1998-05-13
US6472212B1 (en) 2002-10-29
WO1993007281A1 (en) 1993-04-15
DE69225489D1 (de) 1998-06-18
US5612206A (en) 1997-03-18

Similar Documents

Publication Publication Date Title
NL9101680A (nl) Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
Kwok et al. Retroviral transfer of genes into canine hemopoietic progenitor cells in culture: a model for human gene therapy.
US5219740A (en) Retroviral gene transfer into diploid fibroblasts for gene therapy
Dunbar et al. Gene transfer into hematopoietic progenitor and stem cells: progress and problems
US6027722A (en) Vectors for gene transfer
US6287863B1 (en) Method of transferring a DNA sequence to a cell in vitro
JP2000512150A (ja) 細胞を形質転換するための方法および組成物
Havenga et al. Retroviral stem cell gene therapy
Williams et al. Somatic gene therapy. Current status and future prospects.
Morgan et al. Retroviral gene therapy in Germany with a view on previous experience and future perspectives
Kaptein et al. Optimized conditions for the production of recombinant amphotropic retroviral vector preparations
US20030157070A1 (en) High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
Larochelle et al. Genetic manipulation of hematopoietic stem cells
Chu et al. Retrovirus-mediated gene transfer into human hematopoietic stem cells
Kantoff et al. Prospects for gene therapy for immunodeficiency diseases
US5837536A (en) Expression of human multidrug resistance genes and improved selection of cells transduced with such genes
JPH11514209A (ja) 組換えレトロウイルス調製物による造血幹細胞の高効率エクスビボ形質導入
Bernstein et al. Gene transfer with retrovirus vectors
US6534314B1 (en) Methods and compositions for transforming cells
CA2244663A1 (en) 10a1 retroviral packaging cells and uses thereof
JPH11503916A (ja) 高力価組換えレトロウイルス調製物による細胞の高効率エクスビボ形質導入
Karlsson Gene therapy of haematopoietic cells
CA2283641A1 (en) Methods and compositions for genetically modifying primate bone marrow cells
Moore et al. Optimizing conditions for gene transfer into human hematopoietic cells
Robbins Retroviral vectors

Legal Events

Date Code Title Description
A1B A search report has been drawn up
BV The patent application has lapsed